BFD-22

BFD-22 is a benzofuroxan derivative identified as a **potential inhibitor of BRAF kinase**, notable for its **anti-metastatic and antitumor effects against melanoma**. In vitro and in vivo studies in melanoma models demonstrate its ability to induce apoptosis, inhibit cell proliferation, suppress migration and invasion of tumor cells, and arrest the cell cycle at G0/G1 phase by reducing cyclin D1 and CDK4 expression. Mechanistically, BFD-22 binds into the ATP catalytic site of BRAF, strongly downregulating BRAF phosphorylation at Ser338, similar to sorafenib. It showed better **antimetastatic efficacy than sorafenib and taxol** in animal models, marking it as a promising lead compound for further melanoma drug development[1][9][11].

Other names

BFD-22BFD22BFD 22benzofuroxan derivative